Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (291-300 of 713) with videos related to

Pageof 72
Sort By:
American Journal of Hematology|January 23, 2016
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Courtney D DiNardo, Guillermo Garcia-Manero, Sherry Pierce, et al.
Blood|June 21, 2003
Rituximab in relapsed or refractory hairy cell leukemiaDeborah A Thomas, Susan O'Brien, Carlos Bueso-Ramos, et al.
Current Cardiology Reports|February 16, 2023
Cardiovascular Toxicities Associated with Tyrosine Kinase InhibitorsNicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, et al.
American Journal of Hematology|October 21, 2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experienceBryan Hennessy, Francis Giles, Jorge Cortes, et al.
Cancer|February 8, 2007
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and ImatinibFlorian Heidel, Jorge Cortes, Frank G Rücker, et al.
Haematologica|January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapyNaveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemiaHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2014
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemiaAlfonso Quintás-Cardama, Nianxiang Zhang, Yi Hua Qiu, et al.
Leukemia Research|December 23, 2014
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosisSrdan Verstovsek, Ronald Hoffman, John Mascarenhas, et al.
British Journal of Haematology|July 9, 2002
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndromeSrdan Verstovsek, Elihu Estey, Taghi Manshouri, et al.
Pageof 72

Showing results (291-300 of 713) with videos related to

Sort By:
Pageof 72
American Journal of Hematology|January 23, 2016
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Courtney D DiNardo, Guillermo Garcia-Manero, Sherry Pierce, et al.
Blood|June 21, 2003
Rituximab in relapsed or refractory hairy cell leukemiaDeborah A Thomas, Susan O'Brien, Carlos Bueso-Ramos, et al.
Current Cardiology Reports|February 16, 2023
Cardiovascular Toxicities Associated with Tyrosine Kinase InhibitorsNicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, et al.
American Journal of Hematology|October 21, 2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experienceBryan Hennessy, Francis Giles, Jorge Cortes, et al.
Cancer|February 8, 2007
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and ImatinibFlorian Heidel, Jorge Cortes, Frank G Rücker, et al.
Haematologica|January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapyNaveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemiaHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2014
Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemiaAlfonso Quintás-Cardama, Nianxiang Zhang, Yi Hua Qiu, et al.
Leukemia Research|December 23, 2014
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosisSrdan Verstovsek, Ronald Hoffman, John Mascarenhas, et al.
British Journal of Haematology|July 9, 2002
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndromeSrdan Verstovsek, Elihu Estey, Taghi Manshouri, et al.
Pageof 72